Phathom Pharmaceuticals (PHAT): Director bought ~$8.1K
James N Topper, Director at Phathom Pharmaceuticals, bought ~$8.1K of Phathom Pharmaceuticals shares.
- ~$8.1K
- Approx. value · 2,226 sh @ $3.62
- 36K
- Holds after · shares reported
- Traded
- May 9, 2025
- Filed
- May 13, 2025
What stands out in this filing
- The purchase added 6.7% to the shares this insider held before it; the filing reports 35,602 shares, held indirectly afterwards.
- 2,226 shares at an average of $3.62 each, as reported on the form.
- 1 other insider at PHAT also bought in the open market within 30 days.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 13, 2025InsiderDirector purchased ~$44K of PHAT shares in the open market
- Apr 7, 2025InsiderCFO sold ~$17K of PHAT shares in the open market
- May 6, 2025InsiderDirector purchased ~$13K of PHAT shares in the open market
- May 7, 2025InsiderDirector purchased ~$12K of PHAT shares in the open market
- May 9, 2025 · this disclosureInsiderDirector purchased ~$8.1K of PHAT shares in the open market
What came next
- May 9, 2025InsiderDirector purchased ~$107K of PHAT shares in the open market
- May 12, 2025InsiderDirector purchased ~$38K of PHAT shares in the open market
- May 13, 2025InsiderDirector purchased ~$3.5K of PHAT shares in the open market
- May 14, 2025InsiderDirector purchased ~$21K of PHAT shares in the open market
- May 21, 2025InsiderDirector purchased ~$15K of PHAT shares in the open market
- Jul 16, 2025InsiderOfficer sold ~$14K of PHAT shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Phathom Pharmaceuticals
For Phathom Pharmaceuticals, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PHAT page.
Other recent filings by James N Topper, Director
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Sep 17, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Sep 10, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Aug 13, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Jun 26, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Jun 26, 2025
The full history of James N Topper, Director is on the profile page.
How this filing works
Explore the data
Common questions
Which Phathom Pharmaceuticals (PHAT) insider traded, and how much?
James N Topper, Director at Phathom Pharmaceuticals, bought ~$8.1K of Phathom Pharmaceuticals shares. 2,226 shares at $3.62, open market.
When did it happen, and when was it made public?
Traded: May 9, 2025. Filed: May 13, 2025. That is 4 days between the two dates.
What stands out in this filing?
The purchase added 6.7% to the shares this insider held before it; the filing reports 35,602 shares, held indirectly afterwards. 2,226 shares at an average of $3.62 each, as reported on the form. 1 other insider at PHAT also bought in the open market within 30 days.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Phathom Pharmaceuticals recently?
For Phathom Pharmaceuticals, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the PHAT page.
Does this mean PHAT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Phathom Pharmaceuticals
- SEC Schedule 13DNov 2, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRFeb 17, 2026
- SEC Form 13F-HROct 20, 2025
- SEC Form 4Sep 9, 2025
- SEC Form 13F-HRAug 14, 2025
Everything OQRO holds on this company is on its PHAT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
